Key Takeaways:
Multiple law firms are reminding investors of the May 22, 2026, deadline to seek lead plaintiff status in a class-action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ: ATRA) for alleged securities law violations.
"If you purchased or acquired securities in Atara between May 20, 2024 and January 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly," the firm stated in a press release. Faruqi & Faruqi, LLP, The Gross Law Firm, The Schall Law Firm, and Rosen Law Firm are among the firms that have issued notices to shareholders.
The lawsuit centers on allegations that Atara made false and misleading statements regarding the approval prospects of its drug candidate, tabelecleucel. The complaint alleges the company failed to disclose manufacturing issues and deficiencies in its ALLELE study, which made FDA approval unlikely. On January 12, 2026, Atara's stock price plummeted $7.79 per share, a 56.99% drop, after the company announced the FDA had issued a Complete Response Letter (CRL) for the drug's Biologics License Application (BLA).
The CRL indicated that the FDA could not approve the BLA in its current form, stating that the single-arm ALLELE trial was no longer considered adequate to provide evidence of effectiveness for accelerated approval. The lawsuit claims that the company overstated the drug's regulatory prospects and subjected itself to a heightened risk of regulatory scrutiny, which was likely to have a significant negative impact on Atara’s business and financial condition.
The class action complaint alleges that throughout the Class Period, Atara Biotherapeutics and its executives violated federal securities laws. The defendants are accused of failing to disclose that manufacturing issues and deficiencies in the ALLELE study made it improbable that the FDA would approve the tabelecleucel BLA. Consequently, the drug's regulatory prospects were overstated, and the company faced a higher risk of regulatory scrutiny.
Investors who purchased Atara securities during the specified period may be entitled to compensation. The lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
The lawsuit seeks to recover damages for investors who suffered losses as a result of the alleged misrepresentations. The decline in Atara's stock price following the FDA's decision represents a significant loss for investors who purchased shares during the class period. The upcoming deadline is a critical date for investors who wish to take a leading role in the litigation.
This article is for informational purposes only and does not constitute investment advice.
